Rechallenge with zongertinib after trastuzumab deruxtecan in HER2-mutant lung cancer: A case report
{{output}}
A 65-year-old man with advanced lung adenocarcinoma underwent comprehensive genomic profile testing using a blood sample after completion of standard therapy, which identified a HER2 mutation. The HER2- tyrosine kinase inhibitor (TKI); zongertinib achieved par... ...
